What is Edgewise Therapeutics Inc (EWTX) stock price today?

Edgewise Therapeutics Inc (EWTX) currently trades at $30.45 per share. The stock has a market capitalization of $3.27B and a P/E ratio of —x.

Is EWTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Edgewise Therapeutics Inc has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 8.87.

Is Edgewise Therapeutics Inc financially healthy?

Edgewise Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 8.87 places it in the safe zone.

EWTX

Edgewise Therapeutics Inc

NASDAQ: EWTX · HEALTHCARE · BIOTECHNOLOGY

$30.45

-1.74% today

Updated 2026-04-29

Market cap

$3.27B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.63

Dividend yield

—

52W range

$12 – $35

Volume

0.9M

Market cap

$3.27B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.63

Dividend yield

—

52W range

$12 – $35

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

8.9

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$41.08

+34.91%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 8.87 — safe zone

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-38.77M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-15.40M	$-100.16M	$-133.81M	$-167.79M	$-50.22M
EPS	—	—	—	—	$-1.63
Free cash flow	$-58.18M	$-97.69M	$-110.34M	$-144.07M	$-38.77M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
EWTX	$3.27B	25	4.3	3.0	5.0	8.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Edgewise Therapeutics Inc trades at $30.45. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 8.87, it sits in the safe zone.

Frequently asked questions

What is Edgewise Therapeutics Inc's stock price?

Edgewise Therapeutics Inc (EWTX) trades at $30.45.

Is Edgewise Therapeutics Inc overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Edgewise Therapeutics Inc (EWTX)?

The analyst target price is $41.08, representing +34.9% upside from the current price of $30.45.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

8.87 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

edgewisetx.com

Quick metrics

P/S ratio—

ROE-34.20%

Beta0.25

50D MA$31.02

200D MA$22.42

Shares out0.11B

Float0.07B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

EWTX vs LLY →EWTX vs JNJ →EWTX vs ABBV →Stock screener →